BR112022018001A2 - Moduladores do receptor x4 de proteína g relacio-nados com mas e produtos e métodos relacionados - Google Patents

Moduladores do receptor x4 de proteína g relacio-nados com mas e produtos e métodos relacionados

Info

Publication number
BR112022018001A2
BR112022018001A2 BR112022018001A BR112022018001A BR112022018001A2 BR 112022018001 A2 BR112022018001 A2 BR 112022018001A2 BR 112022018001 A BR112022018001 A BR 112022018001A BR 112022018001 A BR112022018001 A BR 112022018001A BR 112022018001 A2 BR112022018001 A2 BR 112022018001A2
Authority
BR
Brazil
Prior art keywords
mas
protein
methods
receptor modulators
mrgpr
Prior art date
Application number
BR112022018001A
Other languages
English (en)
Inventor
Sainz Marcos
YEAGER Adam
Selfridge Brandon
Martinborough Esther
Boehm Marcus
Huang Liming
Original Assignee
Escient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Escient Pharmaceuticals Inc filed Critical Escient Pharmaceuticals Inc
Publication of BR112022018001A2 publication Critical patent/BR112022018001A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MODULADORES DO RECEPTOR X4 DE PROTEÍNA G RELACIONADOS COM MAS E PRODUTOS E MÉTODOS RELACIONADOS. A presente invenção refere-se a métodos para modular MRGPR X4 em geral, ou para tratar uma condição dependente de MRGPR X4 mais especificamente, contatando o MRGPR X4 ou administrando, a um indivíduo em necessidade do mesmo, respectivamente, uma quantidade eficaz de um composto com a estrutura de Fórmula (I): (I) ou um isômero, racemato, hidrato, solvato, isótopo ou sal farmaceuticamente aceitável do mesmo, em que m, n, p, t, A, B, Z, R1, R2 e R3 são como aqui definidos. Também são fornecidas composições farmacêuticas contendo tais compostos, bem como os próprios compostos. Os moduladores do receptor X4 de proteína G relacionados com Mas são, em particular, isoindolinonas e isoquinolinonas substituídas no anel carbocíclico. Os compostos são úteis para tratar condições associadas à coceira, condições associadas à dor ou um distúrbio autoimune.
BR112022018001A 2020-04-17 2021-04-15 Moduladores do receptor x4 de proteína g relacio-nados com mas e produtos e métodos relacionados BR112022018001A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063011964P 2020-04-17 2020-04-17
PCT/US2021/027477 WO2021211839A1 (en) 2020-04-17 2021-04-15 Modulators of mas-related g-protein receptor x4 and related products and methods

Publications (1)

Publication Number Publication Date
BR112022018001A2 true BR112022018001A2 (pt) 2022-11-08

Family

ID=75787327

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018001A BR112022018001A2 (pt) 2020-04-17 2021-04-15 Moduladores do receptor x4 de proteína g relacio-nados com mas e produtos e métodos relacionados

Country Status (11)

Country Link
US (1) US11787767B2 (pt)
EP (1) EP4135691A1 (pt)
JP (1) JP2023523545A (pt)
KR (1) KR20230004493A (pt)
CN (1) CN115397412A (pt)
AU (1) AU2021255966A1 (pt)
BR (1) BR112022018001A2 (pt)
CA (1) CA3170064A1 (pt)
IL (1) IL297139A (pt)
MX (1) MX2022011712A (pt)
WO (1) WO2021211839A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023236920A1 (en) * 2022-06-07 2023-12-14 Sironax Ltd. Sarm1 modulators, preparations, and uses thereof
WO2024083210A1 (en) * 2022-10-21 2024-04-25 Hepaitech (Beijing) Biopharma Technology Co., Ltd. Compounds, compositions and methods thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
EP0906283A1 (en) * 1996-06-17 1999-04-07 Smithkline Beecham Plc Substituted benzamide derivatives and their use as anticonvulsants
WO2001049289A1 (en) 1999-12-31 2001-07-12 Texas Biotechnology Corporation Pharmaceutical and veterinary uses of endothelin antagonists
WO2001091796A2 (en) 2000-06-01 2001-12-06 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
MX2009006543A (es) * 2006-12-20 2009-06-26 Amgen Inc Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
AR065810A1 (es) * 2007-03-20 2009-07-01 Celgene Corp Derivados de isoindolina 4'-o-sustituidos,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer y en otros trastornos donde es necesario el control de la angiogenesis o la inhibicion de citoquinas, incluyendo tnf-alfa.
US10383868B2 (en) * 2015-11-28 2019-08-20 Russell Dahl Quinoline containing compounds and their use for treating endoplasmic reticulum stress-related diseases
WO2017133258A1 (zh) * 2016-02-04 2017-08-10 西华大学 1h-吲唑类衍生物及其作为ido抑制剂的用途
CN107033087B (zh) * 2016-02-04 2020-09-04 西华大学 1h-吲唑-4-胺类化合物及其作为ido抑制剂的用途
MX2018009870A (es) * 2016-02-15 2018-11-29 Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh Inhibidores de taf1 para la terapia del cancer.
CN108689937B (zh) * 2017-04-10 2021-09-17 西华大学 吲唑类化合物及其在制备ido抑制剂类药物上的用途
WO2019014100A1 (en) * 2017-07-10 2019-01-17 Celgene Corporation ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF
WO2019147783A1 (en) * 2018-01-25 2019-08-01 Dana-Farber Cancer Institute, Inc. Sulfonamide derivatives for protein degradation
KR102114389B1 (ko) * 2018-05-02 2020-05-25 이화여자대학교 산학협력단 신규 소듐채널 저해 화합물, 이의 제조방법, 및 이를 포함하는 소듐채널 관련 질환의 예방 또는 치료용 약학적 조성물
CN108863892B (zh) * 2018-07-04 2022-04-05 温州医科大学 一种含酰胺结构的没食子酸甲酯类似物及应用
CN110903224A (zh) * 2018-09-18 2020-03-24 复旦大学 一种芳基磺酰胺类化合物、其制备方法、药物组合物及用途
US20210032213A1 (en) * 2019-03-28 2021-02-04 Escient Pharmaceuticals, Inc. Modulators of mas-related g-protein receptor x4 and related products and methods
TWI807201B (zh) * 2019-07-23 2023-07-01 臺北醫學大學 組蛋白去乙醯化酶６抑制劑及治療神經病變性疼痛的方法

Also Published As

Publication number Publication date
CN115397412A (zh) 2022-11-25
EP4135691A1 (en) 2023-02-22
CA3170064A1 (en) 2021-10-21
AU2021255966A1 (en) 2022-11-17
IL297139A (en) 2022-12-01
JP2023523545A (ja) 2023-06-06
WO2021211839A1 (en) 2021-10-21
KR20230004493A (ko) 2023-01-06
US20210340106A1 (en) 2021-11-04
US11787767B2 (en) 2023-10-17
MX2022011712A (es) 2022-10-07

Similar Documents

Publication Publication Date Title
BR112021019256A2 (pt) Moduladores de receptor x4 de proteína g relacionado a mas e produtos e métodos relacionados
BR112022018001A2 (pt) Moduladores do receptor x4 de proteína g relacio-nados com mas e produtos e métodos relacionados
DOP2021000019A (es) Inhibidores de inflamasoma nlrp3
Sousa‐Valente et al. Transient receptor potential ion channels in primary sensory neurons as targets for novel analgesics
BR112021022796A2 (pt) Inibidores de inflamassoma de nlrp3
Gray et al. Long-term potentiation in the hippocampal CA1 region does not require insertion and activation of GluR2-lacking AMPA receptors
BR112022025201A2 (pt) Compostos de sulfonamida de di-hidroquinolina de ciclobutila
BR112022002520A2 (pt) Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer
BR0312924A (pt) Biciclo-pirazóis ativos como inibidores de quinase, processo para sua preparação e composições farmacêuticas compreendendo os mesmos
CL2019002671A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1.
Tang et al. Recent progress on the molecular pharmacology of propofol
CO2024001922A2 (es) Inhibidores de nlrp3
BR0312913A (pt) Ativo de biciclo-pirazóis como inibidores de cinase, processo para sua preparação e composições farmacêuticas compreendendo o mesmo
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
BR112016028642A2 (pt) composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo.
Heyman et al. Tolerability and efficacy of perampanel in children with refractory epilepsy
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112022010377A2 (pt) Novos tiromiméticos
BR112021006398A2 (pt) tratamento de tremor essencial usando (r)-2-(4-isopropilfenil)-n-(1-(5-(2,2,2-trifluoretoxi)piridin-2-il)etil) acetamida
Fasciani et al. Allosteric modulators of G protein-coupled dopamine and serotonin receptors: a new class of atypical antipsychotics
BR112019006216A2 (pt) compostos de p2x3 e/ou p2x2/3 e métodos
Wiedmann et al. Identification of the A293 (AVE1231) binding site in the cardiac two-pore-domain potassium channel task-1: a common low affinity antiarrhythmic drug binding site
Kurlan et al. Carbamazepine-induced tics
BR112018001035A2 (pt) compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos
BR112018015851A2 (pt) composto, e, medicamento.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing